SkinBioTherapeutics to launch new consumer study on acne, beats trading expectations for full year
In partnership with Dutch supplement provider Winclove Probiotics BV, SkinBioTherapeutics will compare two specific blends in a consumer study to target inflammation linked to skin issues like acne. 300 UK participants with acne-prone skin will test the products for eight weeks, recording their experiences in weekly questionnaires. The study will finish in 2023, with results expected in Q1 2024.
In the same statement, SkinBio said that trading for the year ending June 2023 met market expectations, with year-end cash of £1.3m exceeding the expected £1.1m.
Post-year-end, the company expanded AxisBiotix-P availability in France and Italy, launched a consumer study for the Acne product, and initiated additional SkinBiotix™ studies with partner Croda, expected to conclude in Q1 2024.
View from Vox
SkinBioTherapeutics is a life science company focused on skin health. SkinBioTherapeutics’ platform, SkinBiotix®, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. In doing so, SkinBio is exploiting a critical gap in the market for microbiome-based applications.
SkinBioTherapeutics is looking to target three specific areas: cosmetics, infection control and eczema, with these areas representing a combined annual global market of over $100 billion.
The news of SkinBio launching an acne study is well timed, given the global acne market was worth US$10.5 billion in 2022 with CAGR of 5.1%. The UK acne therapeutics market size is at around $261m in 2022 and is projected to reach $377m in 2030, exhibiting a CAGR of 4.7%.
34% of adults in the UK have experienced acne at some time in their lives and 11.5% of adults presently have acne. Overall, this means that acne is the most common skin condition and one of the top 10 most prevalent diseases worldwide.
Follow SkinBioTherapeutics for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.